Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2020 | Thyroid Cancer | Correction

Correction to: Hsa_circ_0058124 promotes papillary thyroid cancer tumorigenesis and invasiveness through the NOTCH3/GATAD2A axis

Authors: Yao Yao, Xinyuan Chen, Hong Yang, Wei Chen, Yichun Qian, Zhongyi Yan, Tian Liao, Weiping Yao, Wenlan Wu, Tonghua Yu, Yun Chen, Yuan Zhang

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2020

Excerpt

Correction to: J Exp Clin Cancer Res …

Yao, et al. Hsa_circ_0058124 promotes papillary thyroid cancer tumorigenesis and invasiveness through the NOTCH3/GATAD2A axis. J Exp Clin Cancer Res. 2019;38:318.CrossRef

Title: Correction to: Hsa_circ_0058124 promotes papillary thyroid cancer tumorigenesis and invasiveness through the NOTCH3/GATAD2A axis
Authors: Yao Yao
Xinyuan Chen
Hong Yang
Wei Chen
Yichun Qian
Zhongyi Yan
Tian Liao
Weiping Yao
Wenlan Wu
Tonghua Yu
Yun Chen
Yuan Zhang
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Thyroid Cancer
Thyroid Cancer
Thyroid Cancer
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2020
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-020-01560-8

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

Perioperative chemo outplays neoadjuvant CRT in esophageal cancer

05-06-2024 Esophageal Cancer News

LAURA heralds practice change for locally advanced NSCLC

03-06-2024 NSCLC News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2020

EIF3H promotes aggressiveness of esophageal squamous cell carcinoma by modulating Snail stability

Metformin-repressed miR-381-YAP-snail axis activity disrupts NSCLC growth and metastasis

Correction to: miR-3928v is induced by HBx via NF-κB/EGR1 and contributes to hepatocellular carcinoma malignancy by down-regulating VDAC3

Promotion of ubiquitination-dependent survivin destruction contributes to xanthohumol-mediated tumor suppression and overcomes radioresistance in human oral squamous cell carcinoma

BRD7 suppresses invasion and metastasis in breast cancer by negatively regulating YB1-induced epithelial-mesenchymal transition

2,6-DMBQ is a novel mTOR inhibitor that reduces gastric cancer growth in vitro and in vivo